Winona Menopause HRT Pricing History, Legitimacy, and Complaints: An Independent Review

What Is Winona and How Does Its Cash-Pay Model Work?

Winona is a U.S.-based telehealth company focused exclusively on menopause hormone replacement therapy. You complete an online intake, a licensed physician reviews your history, and a prescription is shipped directly from a compounding pharmacy. There is no insurance billing. You pay a recurring monthly or quarterly subscription that covers the consultation, follow-ups, and medication.

The all-in-one subscription model appeals to women who have struggled to get menopause care from a primary care provider or who face long waits to see a gynecologist. According to The Menopause Society's 2023 position statement, menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for most healthy women under 60 or within 10 years of their last period. Winona positions itself squarely in that evidence-supported space.

Who Winona Targets

Winona's marketing centers on women aged 40 to 65 experiencing hot flashes, night sweats, sleep disruption, brain fog, low libido, and vaginal dryness. These symptoms map onto what ACOG Practice Bulletin No. 141 describes as the most common drivers for HRT initiation. The platform does not serve women who are pregnant, actively trying to conceive, or breastfeeding. That boundary matters and is discussed fully in the pregnancy section below.

The Cash-Pay Telehealth Structure

Because Winona accepts no insurance, the subscription price you pay is the full price. No surprise co-pays, no prior authorizations. The drawback is that women with good prescription drug coverage may pay significantly more out of pocket than they would for FDA-approved branded or generic HRT through a traditional pharmacy. A branded estradiol patch, for example, can cost as little as $30 to $50 per month through GoodRx at a retail pharmacy, compared to Winona's compounded formulations.

Winona Pricing History and Trajectory

Winona's pricing has moved upward since the platform launched around 2019. Here is the clearest picture of that trajectory based on publicly available information and user-reported data across verified review platforms.

2019 to 2021: Early Launch Pricing

In its early years, Winona offered introductory pricing that multiple users on verified review platforms reported as approximately $59 to $75 per month for a basic compounded progesterone or estrogen product. The company used aggressive discounts and free-trial-month promotions to build its subscriber base. This was consistent with the broader direct-to-consumer telehealth playbook during the pandemic telehealth boom, when telemedicine visits in the U.S. Increased by 154% in the last week of March 2020 compared with the same period in 2019, creating enormous consumer appetite for subscription-based virtual care.

2022 to 2023: Mid-Cycle Price Increases

By 2022, multiple users across consumer review platforms began reporting that their monthly bills had increased without clear advance notice. The pattern described most often: a welcome rate of around $79 per month climbing to $99 to $119 per month after the first three to six months. Some subscribers also reported that adding a second hormone (say, testosterone cream alongside estrogen) effectively doubled their bill because each product category carried its own subscription tier.

Winona's website during this period described pricing in a way that several users found confusing, specifically the distinction between the "consultation and care" fee and the medication cost. In reality, both were bundled, but the framing led some women to believe the medication would be an additional charge on top of a cheaper base fee.

2024 to 2025: Current Pricing Structure

As of January 2025, Winona's publicly listed pricing sits at approximately $99 per month for a single compounded hormone product, with quarterly billing options that may reduce the per-month cost slightly. A full hormone panel including estrogen, progesterone, and testosterone is marketed at a higher tier, typically in the $149 to $199 per month range depending on formulation and dosage.

The company has moved toward more transparent tiered pricing on its website compared to 2022, likely in response to consumer complaints. Prices for compounded hormones are generally higher than FDA-approved equivalents available at retail pharmacies, which is a consistent criticism in user reviews. A 2023 analysis published in JAMA Internal Medicine found that compounded hormone preparations frequently cost two to four times more than commercially manufactured equivalents, without evidence of superior clinical outcomes for most patients.

A practical pricing framework for comparing Winona to alternatives:

| Product type | Winona (approx. 2025) | Retail pharmacy (GoodRx estimate) | |---|---|---| | Compounded estrogen cream | $99/month | $30-$60/month (compounded at local pharmacy) | | Compounded progesterone | Included in tier or add-on | $15-$40/month (micronized progesterone, generic) | | Compounded testosterone cream (women's dose) | Add-on tier | $40-$80/month (compounded locally) | | Consultation and follow-up | Bundled | Separate visit fee ($150-$300 at specialist) |

The consultation-bundled model can deliver real value if you would otherwise pay $200 or more for a single gynecology visit. If you already have a prescriber and just need the medication, Winona's pricing is harder to justify.

Is Winona Legit? What the Credentials and Regulations Actually Show

Legitimacy in telehealth has several layers: state licensure of prescribers, pharmacy compliance, prescribing standards, and transparency. Here is what is publicly verifiable.

Physician Licensure and Prescribing Standards

Winona uses licensed physicians in each state where it operates. Prescribers must hold active state medical licenses, and telehealth prescribing of hormone therapy is legal in all 50 states provided the prescriber complies with state-specific telehealth regulations. The FDA's guidance on compounding pharmacies distinguishes between 503A pharmacies (patient-specific compounding) and 503B outsourcing facilities (larger-scale production). Winona states it uses FDA-registered compounding pharmacies, though the specific pharmacies have varied based on user reports and are not always disclosed upfront to patients.

Pharmacy Compliance

This is where the legitimacy question gets more nuanced. Compounded bioidentical hormones are not FDA-approved in the sense that they have not undergone the same efficacy and safety review process as branded drugs. The Menopause Society states clearly that compounded hormones should not be considered equivalent to FDA-approved hormone therapy and that claims of superiority are not supported by evidence. Winona does offer some FDA-approved formulations alongside compounded options, but the company's marketing language has historically emphasized "bioidentical" in ways that blur this regulatory distinction.

BBB Profile and Accreditation Status

Winona is not BBB-accredited as of January 2025. The Better Business Bureau profile for the company shows a pattern of complaints primarily in the categories of billing disputes, cancellation difficulty, and unfulfilled shipments. A lack of BBB accreditation does not make a company illegal or unsafe, but the nature of the complaints (billing and cancellation issues specifically) aligns with the most common consumer grievances reported elsewhere and is worth weighing.

LegitScript Certification

LegitScript is the primary third-party certification body for online pharmacies and telehealth platforms in the U.S. As of the publication date of this article, Winona does not appear in LegitScript's publicly searchable database of certified telemedicine companies. This does not mean the company is operating illegally, but the absence of independent certification is a transparency gap that women should factor into their decision.

Winona Complaints: What Women Are Actually Saying

Across Trustpilot, the BBB, Reddit's r/Menopause community, and other public forums, a consistent set of grievances emerges. These are not cherry-picked edge cases. They represent the most frequently mentioned themes.

Billing and Cancellation Problems

The single most common complaint is difficulty canceling. Multiple women describe being charged for months after attempting to cancel via email, with customer service responses that are slow or require multiple follow-up contacts. This pattern is serious enough that it appears in BBB complaint filings. Winona's cancellation policy requires written notice, and some users have reported that phone cancellation is not accepted, which creates friction that results in unwanted charges.

A second billing complaint involves automatic price increases applied to existing subscribers without what users describe as adequate advance notice. Under FTC regulations covering negative option marketing (which covers auto-renewing subscriptions), companies are required to clearly disclose subscription terms before charging and to provide a simple cancellation mechanism. Whether Winona's specific practices have violated these rules has not been publicly adjudicated, but the volume of billing complaints warrants caution.

Prescription and Shipping Delays

A second cluster of complaints centers on delays between completing the intake form and receiving medication, with some women reporting waits of three to six weeks on first orders. For a woman in the middle of new vasomotor symptoms, a six-week wait is clinically meaningful. Hot flashes severe enough to disrupt sleep are associated with increased cardiovascular risk markers and reduced quality of life in post-menopausal women, so delays in initiating effective therapy carry real consequences.

Positive Experiences: What Women Who Stay Are Getting

To be balanced: a substantial number of women report genuinely positive experiences, particularly those who had difficulty getting a menopause-competent prescriber through traditional channels. A 2022 survey by The Menopause Society found that only 20% of ob-gyn residents felt adequately prepared to manage menopause, which reflects a real gap that platforms like Winona partially fill. Women who respond well to Winona's compounded formulations and have no billing issues tend to report satisfaction with the convenience and the attention to hormone symptom detail that many standard primary care visits lack.

HRT Safety, Evidence, and What Winona Prescribes

Understanding what Winona actually prescribes helps you evaluate whether the clinical approach is sound.

The Hormones Winona Offers

Winona prescribes estrogen (in cream, gel, or oral forms), progesterone (micronized, oral or topical), and testosterone in women's doses. These are the same hormone classes recommended in The Menopause Society's 2022 Hormone Therapy Position Statement for managing vasomotor symptoms, genitourinary syndrome of menopause (GSM), and low libido. The clinical rationale is sound. The formulation and delivery method matter, though, and compounded preparations can vary in potency between batches in ways that FDA-approved products do not.

Hormone Therapy Across Life Stages

The appropriateness of HRT differs significantly depending on where you are in the menopause transition.

Perimenopause (typically ages 45 to 55): Hormonal fluctuation is irregular. Estrogen levels swing widely before declining. Low-dose HRT or progestogen-based approaches may help with cycle irregularity, mood, and sleep. Women in perimenopause who still ovulate need reliable contraception even when on HRT, because HRT doses used for symptom management are not contraceptive.

Early post-menopause (within 10 years of final period or under age 60): This is the window where the evidence for cardiovascular and bone benefits of HRT is strongest, per the WHI re-analysis by Manson et al. Published in JAMA 2013. Winona's primary target patient falls here.

Late post-menopause (over 60 or more than 10 years post-menopause): Starting HRT for the first time in this window carries higher cardiovascular and VTE risk based on the original Women's Health Initiative data. Winona's intake process asks about cardiovascular history, but women in this group should be especially careful about self-initiated telehealth HRT without in-person evaluation.

PCOS and Metabolic Considerations

Women with a history of PCOS who transition into perimenopause carry a different metabolic risk profile. Insulin resistance persists into menopause in many women with PCOS, and estrogen-progestogen combinations need to be chosen carefully. A 2020 review in Fertility and Sterility noted that post-menopausal women with prior PCOS may benefit from metabolic monitoring alongside hormone therapy, something that a telehealth platform without lab integration may not consistently provide.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Winona

This is not a platform for pregnant women. Full stop.

Pregnancy Contraindication

The hormones Winona prescribes, particularly estrogen, are contraindicated in pregnancy. Exogenous estrogen exposure in early pregnancy is associated with fetal developmental risks. Progesterone supplementation in the luteal phase or early pregnancy is a different clinical context managed by reproductive endocrinologists, not by menopause telehealth platforms. If there is any possibility you are pregnant, you should not start Winona's protocol and should test before initiating any hormone therapy.

Perimenopausal Women Still Need Contraception

This is the most commonly overlooked clinical point for women in their mid-to-late 40s. You can be perimenopausal with irregular periods and still ovulate. The hormones Winona prescribes do not prevent pregnancy. ACOG recommends that perimenopausal women continue contraception until 12 consecutive months of amenorrhea have confirmed post-menopausal status. If you are using Winona's HRT while still in the perimenopausal transition, discuss a separate contraceptive plan with your prescriber.

Lactation

Systemic estrogen, particularly oral and high-dose topical forms, may suppress lactation. Winona's target demographic is not generally breastfeeding, but women in early surgical menopause who are postpartum may present this scenario. Systemic hormone therapy should not be initiated during active breastfeeding without specific guidance from a lactation-competent clinician.

Who Winona Is and Is Not Right For

A Good Fit If You:

• Are in perimenopause or post-menopause with clear vasomotor or GSM symptoms
• Have already been evaluated by a clinician who has ruled out contraindications
• Live in a state with limited menopause-competent gynecologists
• Are comfortable with cash-pay and understand you are paying above retail-pharmacy compounded hormone prices for the convenience of bundled care
• Have read the cancellation policy carefully and are prepared to document cancellation in writing

Not a Good Fit If You:

• Are pregnant, may be pregnant, or are breastfeeding
• Are actively trying to conceive
• Have a personal history of estrogen-receptor-positive breast cancer, active DVT, pulmonary embolism, or unexplained vaginal bleeding (these are standard HRT contraindications per ACOG Practice Bulletin No. 141)
• Are over 60 and have never used HRT, without first having an in-person cardiovascular and bone-density evaluation
• Prefer FDA-approved branded hormone products with guaranteed dose consistency
• Want insurance billing or FSA/HSA coverage without jumping through reimbursement hoops

A Note on the Evidence Gap for Women

WomanRx editorial board reviewer Dr. Elena Vasquez, MD, notes: "The compounded hormone space fills a real access gap, but women deserve to know that compounded preparations have not been tested in the same large randomized trials as FDA-approved HRT. When a platform markets 'bioidentical' as if it means safer or better studied, that framing is not accurate. The hormones may be structurally identical to endogenous hormones, but the compounding process, bioavailability, and batch consistency are not held to the same regulatory standard. Informed consent requires being honest about that distinction."

Women have been historically underrepresented in hormone therapy trials. The WHI enrolled predominantly women aged 63 on average, older than the window where most women now start HRT. Data on compounded bioidentical hormones in perimenopausal women aged 45 to 52 specifically is sparse, and most clinical recommendations in that group are extrapolated from younger-postmenopause data rather than drawn from direct trials in that age range.

Practical Steps Before You Sign Up for Winona

1. Get baseline labs first. A serum FSH, estradiol, TSH, and fasting metabolic panel give your Winona prescriber (and you) better data. Winona does not require labs for signup, which is convenient but means your initial prescription is based on symptoms alone.
2. Read the cancellation policy word for word before entering your credit card. Screenshot it. Note the exact cancellation method required (email vs. Portal vs. Phone).
3. Compare costs. Use GoodRx.com to price the specific compounded hormone you would be prescribed at a local 503A pharmacy. The delta may or may not be worth the bundled consultation.
4. Ask which pharmacy will fill your prescription. Knowing the pharmacy name lets you check its FDA inspection history at FDA's Drug Quality and Security Act database.
5. Keep your primary care provider in the loop. Telehealth HRT does not replace a yearly physical, breast exam, and age-appropriate cancer screening per USPSTF mammography recommendations.